Nov 30, 2020 7:00am EST Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
Nov 24, 2020 7:00am EST Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)
Nov 23, 2020 7:00am EST Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET
Nov 16, 2020 7:00am EST Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
Nov 09, 2020 7:00am EST Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020
Oct 13, 2020 7:00am EDT Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
Sep 30, 2020 7:00am EDT Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference
Sep 08, 2020 7:00am EDT Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
